Axillary Node Dissection Versus no Dissection in Breast Cancer With Positive Sentinel Lymph Node

  • End date
    Jul 24, 2028
  • participants needed
  • sponsor
    Institut Paoli-Calmettes
Updated on 24 January 2021
endocrine therapy
hormone therapy
tumor cells
sentinel node


Data from cohorts, prospective studies and one randomized trial (ASCOG Z0011) support the hypothesis that omission of additional axillary dissection in case of positive sentinel node has a limited impact on overall survival and relapse free survival. However, these data are not sufficient enough to recommend, as a standard of care, to avoid axillary dissection in case of positive sentinel node. The ASCOG Z0011 trial has been closed before the end of inclusions and the predefined non inferiority margin was found to be too large (5% difference at 5 years for primary endpoint).

Prospective randomized trial is then urgently mandatory before omission of axillary node dissection becomes a usual practice without a sufficient scientific level of proof. Indeed, in several reviews, the rate of omission of axillary node dissection in case of micrometastasis increased (Bilimoria) despite any strong proof has been demonstrated.

The omission of axillary node dissection in case of positive sentinel node may have strong practical impacts on patients but also on medical and economical aspects: in avoiding a prolonged hospitalisation, secondary morbidities due to axillary dissection requiring secondary care and their costs, as well as costs for secondary axillary dissection (14 to 25% in case of positive sentinel node) and finally shortening surgery duration.

The main investigator propose a Non Inferiority Randomized Multicenter Phase III Trial of Axillary Node Dissection Versus no Axillary Node Dissection in Case of Positive Sentinel Lymph Node in Invasive Breast Cancer

Condition Invasive Breast Cancer
Treatment Surgery for standard axillary node dissection, No axillary lymph node dissection
Clinical Study IdentifierNCT01717131
SponsorInstitut Paoli-Calmettes
Last Modified on24 January 2021


Yes No Not Sure

Inclusion Criteria

\- Patient aged 18 years and above
\- Patient with invasive breast cancer histologically proven or cytologically proven by fine needle biopsy
\- Patient with a unifocal tumor T0 - T1 - T2 up to 5 cm (clinical or in imagery), without previous therapy (neoadjuvant chemotherapy or hormone therapy)
\- Patient with clinical N0 status
\- Absence of clinically detectable metastases known
- Patients for whom conservative surgery with sentinel lymph node (SLN)
technique is feasible from the start in terms of carcinologic
-All patients with lymph node involvement (GS+), whatever the size of the
metastasis (macro-metastasis, micro-metastasis, cellular cluster or isolated
tumor cells)
- Patient affiliated to a social security system or benefiting from such a
- Signed consent to participate

Exclusion Criteria

\- Tumor of more than 5 cm
\- Indication of neoadjuvant therapy by chemotherapy or hormone therapy
\- History of breast cancer (ipsilateral, ie recurrence, or contralateral breast)
\- History of any other invasive cancer other than a past cutaneous cancer correctly treated
\- Initial metastatic disease known
\- Presence of clinical axillary adenopathy
\- Contra-indication to surgical excision
\- Contra-indication to the SLN technique
\- Pregnant women, of child-bearing potential, or lactating women
- Patient deprived of liberty or under supervision of a guardian
- Impossibility to undergo medical examinations of the study for
geographical, social or psychological reasons
Clear my responses

How to participate?

Step 1 Connect with a study center
What happens next?
  • You can expect the study team to contact you via email or phone in the next few days.
  • Sign up as volunteer to help accelerate the development of new treatments and to get notified about similar trials.

You are contacting

Investigator Avatar

Primary Contact



Additional screening procedures may be conducted by the study team before you can be confirmed eligible to participate.

Learn more

If you are confirmed eligible after full screening, you will be required to understand and sign the informed consent if you decide to enroll in the study. Once enrolled you may be asked to make scheduled visits over a period of time.

Learn more

Complete your scheduled study participation activities and then you are done. You may receive summary of study results if provided by the sponsor.

Learn more

Similar trials to consider


Browse trials for

Not finding what you're looking for?

Every year hundreds of thousands of volunteers step forward to participate in research. Sign up as a volunteer and receive email notifications when clinical trials are posted in the medical category of interest to you.

Sign up as volunteer

user name

Added by • 



Reply by • Private

Lorem ipsum dolor sit amet consectetur, adipisicing elit. Ipsa vel nobis alias. Quae eveniet velit voluptate quo doloribus maxime et dicta in sequi, corporis quod. Ea, dolor eius? Dolore, vel!

  The passcode will expire in None.

No annotations made yet

Add a private note
  • abc Select a piece of text from the left.
  • Add notes visible only to you.
  • Send it to people through a passcode protected link.
Add a private note